AriBio said Tuesday that it has received an initial upfront payment of $10 million from China’s Fosun Pharma under its recently signed global exclusive licensing agreement for AR1001.
The payment represents part of the total $60 million upfront fee included in the agreement and was transferred just 10 days after the deal was announced.
(Credit: AriBio)
The rapid transfer is being viewed as a symbolic case that helps ease market concerns surrounding the “payment risk” often associated with biotech licensing deals, where announced technology exports are sometimes followed by delays in actual fund transfers.
In particular, China is widely known for requiring lengthy approval procedures through the State Administration of Foreign Exchange (SAFE), with large overseas royalty payments typically taking several months to process. Despite this, Fosun Pharma executed part of the upfront payment immediately after the contract announcement, a move analysts say reflects strong confidence in AR1001’s global commercialization potential and clinical success prospects.
Industry observers say the confirmed cash inflow signals that AR1001 is moving beyond the development pipeline stage and entering the full-scale global commercialization phase.
AriBio’s global phase 3 clinical trial for AR1001, known as POLARIS-AD, is currently nearing completion across 13 countries with approximately 1,500 participants enrolled worldwide. Notably, around 95 percent of patients have joined the extension study, while long-term treatment data continues to accumulate .
A high participation rate in the extension study is considered a key indicator of both the drug’s safety profile and patient confidence in long-term treatment. Ahead of the completion of the global phase 3 trial and the release of topline data, the market is also closely watching whether AR1001 could become the world’s first oral treatment for Alzheimer's disease.
According to the company, Fosun Pharma is also proceeding with domestic regulatory procedures in China to complete payment of the remaining $50 million upfront fee by June, with the process reportedly progressing smoothly.
Meanwhile, AriBio is pursuing a merger with Kosdaq-listed Solux and plans to expand into a future convergence platform business connecting AI, data centers, and biotechnology.
Lee Han-soo
댓글
0